These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67. Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids. Bujak E; Pretto F; Neri D Invest New Drugs; 2015 Aug; 33(4):791-800. PubMed ID: 25983040 [TBL] [Abstract][Full Text] [Related]
68. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962 [TBL] [Abstract][Full Text] [Related]
69. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. Mackey JR; Ramos-Vazquez M; Lipatov O; McCarthy N; Krasnozhon D; Semiglazov V; Manikhas A; Gelmon KA; Konecny GE; Webster M; Hegg R; Verma S; Gorbunova V; Abi Gerges D; Thireau F; Fung H; Simms L; Buyse M; Ibrahim A; Martin M J Clin Oncol; 2015 Jan; 33(2):141-8. PubMed ID: 25185099 [TBL] [Abstract][Full Text] [Related]
72. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. Lorusso V; Gebbia V; Spada M; Guida M; Cassano G; Brunetti C; Germano D; Nettis G; Izzi G; Galetta D; Giampaglia M; Silvestris N; Colucci G Oncol Rep; 2005 Dec; 14(6):1547-51. PubMed ID: 16273254 [TBL] [Abstract][Full Text] [Related]
73. Docetaxel (taxotere) in the treatment of non-small cell lung cancer. Georgoulias V Curr Med Chem; 2002 Apr; 9(8):869-77. PubMed ID: 11966449 [TBL] [Abstract][Full Text] [Related]
74. Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer. Paz-Ares LG; Pérol M; Ciuleanu TE; Kowalyszyn RD; Reck M; Lewanski CR; Syrigos K; Arrieta O; Prabhash K; Park K; Pikiel J; Göksel T; Lee P; Zimmermann A; Carter GC; Alexandris E; Garon EB Lung Cancer; 2017 Oct; 112():126-133. PubMed ID: 29191585 [TBL] [Abstract][Full Text] [Related]
75. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S; Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639 [TBL] [Abstract][Full Text] [Related]
76. Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC). Felip E; Rosell R Ther Clin Risk Manag; 2008 Jun; 4(3):579-85. PubMed ID: 18827853 [TBL] [Abstract][Full Text] [Related]
77. SapC-DOPS - a Phosphatidylserine-targeted Nanovesicle for selective Cancer therapy. N'Guessan KF; Patel PH; Qi X Cell Commun Signal; 2020 Jan; 18(1):6. PubMed ID: 31918715 [TBL] [Abstract][Full Text] [Related]
78. New Therapeutic Strategies in Retinal Vascular Diseases: A Lipid Target, Phosphatidylserine, and Annexin A5-A Future Theranostic Pairing in Ophthalmology. Frostegård A; Haegerstrand A Pharmaceuticals (Basel); 2024 Jul; 17(8):. PubMed ID: 39204083 [TBL] [Abstract][Full Text] [Related]
79. BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy. Chen YY; Lo CF; Chiu TY; Hsu CY; Yeh TK; Chen CP; Huang CL; Huang CY; Wang MH; Huang YC; Ho HH; Chao YS; Shih JC; Tsou LK; Chen CT Transl Oncol; 2021 Jan; 14(1):100897. PubMed ID: 33069101 [TBL] [Abstract][Full Text] [Related]
80. Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer. Stasi I; Cappuzzo F Lung Cancer (Auckl); 2014; 5():43-50. PubMed ID: 28210141 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]